A hemophilia treatment center (HTC) is a functional unit organized for and capable of providing coordinated, multidisciplinary comprehensive care for persons with hemophilia and related bleeding disorders.

The purpose of the center is to provide the comprehensive health care services necessary for the accurate diagnosis and continuing expert evaluation and management of inherited bleeding disorders and their complications. The goals include preventing or minimizing disease complications and disability and maximizing patient functional status and quality of life. Comprehensive care also ensures continuity of care from the HTC to the home and community.

The bleeding disorder health care team is responsible for the supervision and coordination of all aspects of the patient's bleeding disorder evaluation and care. Hemophilia treatment centers are located in geographic areas of demonstrated need. People with hemophilia and their families have the freedom to utilize the HTC of their choice and actively participate in decision making regarding their own health care. 

The HTC at Rush University Medical Center is the largest hemophilia and thrombophilia program in Illinois, offering a full menu of clinical and laboratory services onsite for patients with bleeding and clotting disorders. Our federally funded program collaborates with the Department of Health and Human Services, the Great Lakes Hemophilia Foundation, the National Hemophilia Foundation and the Centers for Disease Control and Prevention to provide state-of-the-art, family-focused, culturally sensitive medical, psychological and social services.

The HTC at Rush treats patients with hemophilia, other hereditary coagulation factor deficiencies, von Willebrand disease and platelet disorders, as well as patients with thrombosis and thrombophilia. To make it easier for patients to access our services, we offer diagnosis and treatment services at the main Rush University Medical Center campus near downtown Chicago, and at five regional outreach locations in Aurora, Hoffman Estates, Kankakee, Joliet and Champaign.

There are 134 federally funded HTCs in the United States. Not all HTCs offer clinical services to patients with clotting disorders.  For more information related to the role and benefits of hemophilia treatment centers, see the National Hemophilia Foundation website.